linjc16/ctgov huggingface dataset:
Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar

Study Overview
=================
Brief Summary
-----------------
Artemisinin resistance have been documented in Myanmar and Myanmar artemisinin resistance containment measures have been launched since 2009-2010. It is important to monitor the spread and magnitude of artemisinin resistant malaria in Myanmar. So, day-3 surveillance study have been conducted. Recently artemisinin resistant molecular marker, K13 have been identified and it was used as a tool in this study.

Official Title
-----------------
Molecular Assessment of Artemisinin Resistance Markers, K13 Kelch Propeller and Multi-drug Resistant Gene Polymorphism in Eastern and Western Border Areas of Myanmar

Conditions
-----------------
Day-3 Positive of Parasitaemia, Prevalence of Drug Resistance Gene Mutation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed uncomplicated falciparum malaria patients. age >2 years box sex given informed consent Exclusion Criteria: severe malaria did not give informed consent others diseases

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| day-3 parasite positivity | All of the enrolled patients were monitored with appropriate care up to third day and take the samples on day-3. | 3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of the drug resistance marker | By using the dried blood spots, drug resistance markers were detected by molecular method. | up to day-3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
malaria, K13, pfmrp1, Myanmar
Burden of Influenza at Emergency Department (ED) Level in European Countries

Study Overview
=================
Brief Summary
-----------------
This study plans to conduct enhanced influenza surveillance at a hospital emergency department level independent of underlying influenza-like symptoms.

Detailed Description
-----------------
Study objectives Primary: - Measure the proportion of non-traumatic emergency department (ED) visits infected with influenza during the peak of the influenza season Secondary: Describe the demographic and medical profile of influenza-related and non-influenza-related visits Identify socio-demographic or other risk factors associated with ED visit outcome Describe the influenza positivity rate among ED visits for different causes Measure the proportion of influenza positive patients without classical ILI symptoms

Official Title
-----------------
Burden of Influenza at Emergency Department (ED) Level in European Countries

Conditions
-----------------
Influenza, Human

Intervention / Treatment
-----------------
* Procedure: swab sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adult patients seeking care at participating ED during the influenza season Participants and/or guardian providing informed consent and/or assent, as appropriate, to participate. Exclusion Criteria: Individuals reporting having suffered a traumatic injury without other conditions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Influenza<br>Influenza testing | Procedure: swab sampling<br>* Multiplex polymerase chain reaction assay for organisms of upper respiratory tract infections<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| influenza status at admission to ED (positive vs. negative) | proportion of non-traumatic emergency department (ED) visits infected with influenza during the peak of the influenza season | at admission to ED | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| demographic and medical profile | demographic and medical profile of influenza-related and non-influenza-related visits | at admission to ED | 
| socio-demographic or other risk factors | Identify socio-demographic or other risk factors associated with ED visit outcome | at admission to ED | 
| influenza without classical symptoms of influenza-like illness | Measure the proportion of influenza positive patients without classical ILI symptoms | at admission to ED | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
emergency room, epidemiology
Ultrasound Utility in Routine Clinical Practise

Study Overview
=================
Brief Summary
-----------------
The aim of this research study is to describe the impact of rheumatologist performed ultrasound on the diagnosis and management pathways of patients with rheumatoid arthritis. Primarily, to compare the time from first visit to treatment initiation between patients with and without rheumatologist-performed ultrasound assessment.

Detailed Description
-----------------
There are currently no guidelines for best practice in the use of ultrasound in RA and interim results from a survey by the British Society of Rheumatology (BSR) in this area have suggested that practice is variable across the UK. NICE recognize that the earlier persistent synovitis is identified and treated with disease modifying anti-rheumatic drugs DMARDs, the better the long term outcome and have welcomed the need to determine the role of imaging in assisting with this early diagnosis, and whether the added cost is justified by better disease outcomes. This is a multi-site prospective observational study which investigates the use of ultrasound imaging in the context of patients with early arthritis presenting to secondary care. The time to commencement of DMARD therapy and diagnosis of Rheumatoid arthritis are therein outcome measures. Patients are followed up for 12 months after their first presentation and time to diagnosis or DMARD commencement recorded.

Official Title
-----------------
The Impact of Rheumatologist-performed Ultrasound on Diagnosis and Management of Inflammatory Arthritis in Routine Clinical Practice

Conditions
-----------------
Arthritis, Rheumatoid, Ultrasonography

Intervention / Treatment
-----------------
* Drug: DMARD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≥18 years at the time of presentation to the clinic Patients newly presenting to the rheumatology clinic with suspected inflammatory arthritis Exclusion Criteria: For the non-ultrasound arm; patients who have been referred to another rheumatologist or radiologist for ultrasound Patients who decline or who are unable to consent to the use of their medical records for research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ultrasound<br>Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic | Drug: DMARD<br> <br> |
| Non-Ultrasound<br>Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic | Drug: DMARD<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the time from first visit to treatment initiation between patients with and without rheumatologist-performed ultrasound assessment |  | 12 months |
Burnout Determinants Among Pediatric Psychiatry Workers During COVID-19 Crisis

Study Overview
=================
Brief Summary
-----------------
Burnout among health workers is at core of our current preoccupations because of the health crisis we're going trough. Indeed, COVID-19 epidemic had terrible consequences not only on global mental health both in adults and children, but also on Health workers mental health. The investigators chose to consider Pediatric Psychiatry workers because of their particular position in this crisis. The aim of the study is to point out burnout determining factors among Pediatric Psychiatry workers in Occitanie during COVID-19 crisis, by the use of an online questionnaire including the Copenhagen Burnout Inventory.

Official Title
-----------------
Burnout Determinants Among Pediatric Psychiatry Workers During COVID-19 Epidemic in Occitanie Region in France

Conditions
-----------------
Burnout

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Medical doctors, interns, Paramedics (nurse, assistant nurse), Psychologists, Caseworkers working > 50% in a structure medico socio sanitaire Exclusion criteria: - Other persons working in a in a structure medico socio sanitaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Copenhagen Burnout Inventory | Copenhagen Burnout Inventory, comprising two subscales assessing general and patients-related burnout. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemic attribuable stress proportion | Declarative quantitative assessment of COVID-19 epidemic attribuable stress proportion | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Burnout status
Treatment of Patients With Acute Sinusitis

Study Overview
=================
Brief Summary
-----------------
For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.

Official Title
-----------------
Treatment of Patients With Acute Sinusitis in Daily Practice

Conditions
-----------------
Acute Bacterial Sinusitis

Intervention / Treatment
-----------------
* Drug: Avelox (Moxifloxacin, BAY12-8039)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in accordance with the local production information. Exclusion Criteria: Those specified in the local product information - contraindications and precautions must be considered.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Avelox (Moxifloxacin, BAY12-8039)<br>* Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of |  | Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of tolerability and safety of Avalox® in daily practice were investigated. |  | Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days). | 
| Patient characteristics in acute bacterial sinusitis |  | Documentation at baseline visit. | 
| History and frequency of sinusitis episodes |  | Documentation at baseline visit. | 
| Diagnostic procedures and therapeutic options chosen by physicians in daily practice |  | Documentation at baseline visit. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Moxifloxacin, MXF, Avelox, Sinusitis, Acute bacterial sinusitis, ABS
Special Survey for Long Term Application

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia without epiphyseal line closure under normal clinical practice conditions.

Official Title
-----------------
Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application

Conditions
-----------------
Genetic Disorder, Achondroplasia

Intervention / Treatment
-----------------
* Drug: somatropin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Achondroplasia without epiphyseal line closure

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Somatropin<br> | Drug: somatropin<br>* Prescription of somatropin at the discretion of the physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reactions (ADRs) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment evaluation using the Foundation for Growth Science's Criteria for Treatment Continuation: Definitely effective, effective, ineffective or definitely ineffective |  |  |
Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida

Study Overview
=================
Brief Summary
-----------------
This study evaluates whether adding a dietary supplement similar to coconut oil (MCT oil) to feedings in premature infants will reduce the amount of yeast (Candida) detectable in their stool. Infants who have Candida in their stool are eligible to participate. Half of the enrolled infants will have additional MCT oil added to their feedings and half will not.

Official Title
-----------------
Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida

Conditions
-----------------
Candida Infection, Premature Infant

Intervention / Treatment
-----------------
* Drug: Medium-Chain Triglyceride (MCT) Oil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Premature infant admitted to the Neonatal Intensive Care Unit at Women & Infants Hospital Receiving full enteral feeds of either preterm or transitional formula or fortified breast milk Anticipated to have a minimum stay of two weeks Exclusion Criteria: Prior exposure to antifungal drugs

Ages Eligible for Study
-----------------
Maximum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>This group receives no feeding supplement. | |
| Experimental: MCT Oil<br>This group is supplemented with MCT oil | Drug: Medium-Chain Triglyceride (MCT) Oil<br>* Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stool Fungal Burden | Change in colony-forming units (cfu) of Candida per gram of stool. Data table reflects total number of stool samples collected from subjects in each group that were included in the analysis. | Before supplementation, 1 week after supplementation begins, 3 weeks (at conclusion of supplementation) |
Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to assess the long-term safety and tolerability of EC-MPS on the patients who completed the core study and wish to continue treatment on EC-MPS.

Official Title
-----------------
Efficacy and Safety of Two Immunosuppressive Regimens Mycophenolate Sodium (EC-MPS) With Short-term Steroid Use or Free of Steroids Compared With a Regimen of EC-MPS With Standard Steroids in de Novo Kidney Recipients

Conditions
-----------------
Renal Transplantation

Intervention / Treatment
-----------------
* Drug: Enteric-coated Mycophenolate sodium (EC-MPS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria/ Exclusion Criteria All patients who completed the core study and who are still receiving the EC-MPS and wish continue treatment with EC-MPS and from whom written informed consent has been obtained Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Enteric-coated Mycophenolate sodium (EC-MPS)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability of enteric-coated mycophenolate sodium based on adverse event (AE) reporting. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal/Kidney, Transplantation, steroids, EC-MPS
Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer

Study Overview
=================
Brief Summary
-----------------
Despite performing colonic surgery with strict asepsia measures, minimizing the contact of the colon lumen with the peritoneum, some contamination is nearly impossible to avoid. In stapled anastomosis, the hole opened in the colon is minimum, just the necessary for introducing the parts of the mechanical devices. In handsewn anastomosis, the colonic lumen is more exposed to the peritoneum, despite the colonic occlusion with clamps meanwhile the suture is performed. Hypothesis: After stapled anastomoses, the peritoneal contamination should be lower than after handsewn ones.

Official Title
-----------------
Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer: Are There Differences in the Peritoneal Contamination After Performing a Stapled or a Handsewn Anastomosis?

Conditions
-----------------
Peritoneal Contamination After Ileocolonic Anastomosis, Wound Infection, Intra-abdominal Abscess

Intervention / Treatment
-----------------
* Procedure: Stapled anastomosis
* Procedure: Handsewn anastomosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of right-sided colon cancer and plans to undergo an elective surgery with curative aims.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Handsewn ileocolonic anastomosis<br>Swabs obtained from patients undergoing handsewn ileocolonic anastomosis | Procedure: Handsewn anastomosis<br>* Handsewn anastomosis after ileocolonic resection<br>|
| Experimental: Stapled ileocolonic anastomosis<br>Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis | Procedure: Stapled anastomosis<br>* Stapled anastomosis after ileocolonic resection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peritoneal contamination after finishing the ileocolonic anastomosis | Swabs will be obtained from the peritoneal surface for microbiological culture | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Right-sided colon cancer, Ileocolonic anastomosis, stapled anastomosis, handsewn anastomosis, peritoneal contamination, microbiological spectrum